Clinical Trials Directory

We are doing this study to find out if an experimental drug called abatacept (the study drug) is a safe and effective option to help prevent graft-versus-host (GVHD) disease for people who get an omidubicel hematopoietic stem cell transplant to treat blood cancer. Omidubicel is a recently approved (2023) stem cell transplantation that uses modified umbilical cord blood. This new method of stem cell transplantation helps patients' immune systems recover more quickly after intensive chemotherapy.

We are doing this study to learn if hyperbaric oxygen therapy is helpful to people with traumatic brain injury.

If you agree to be in the study, you will have 1 study visit that will last about 4 hours. The visit will include asking questions about your medical history, vital signs, pulmonary function tests (PFTs) and an MRI (magnetic resonance image) of the chest with inhaled Xenon gas. Someone from the study team will contact you about 24 hours after your study visit.

We are doing this study to find out if an experimental drug called dazodalibep (the study drug) can improve symptoms for people who have Sjogren's Syndrome.

We are doing this study to analyze biomarker responses to different drug regimens used for people who have HER2- and HER2+ breast cancer. We hope what we learn from the study can help us develop better treatments and figure out which treatment option(s) will be best for breast cancer patients.

We are doing this study to find the most effective, safe dose of an experimental drug called IAM1363 (the study drug) for people who have advanced cancers harboring HER2 alterations.

We are doing this study to find the most effective, safe dose of an experimental drug called iberdomide (the study drug). We want to know how well this study drug works in people with multiple myeloma when compared with a drug called lenalidomide after an autologous stem cell transplant.

We are doing this study to compare the outcomes and results of two newer asthma relief therapies (called MART and PARTICS). We want to know if either option seems to be more effective for most people with moderate-to-severe asthma.